Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2025 16:30 ET | Source: Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T. on...
February 18, 2025 06:00 ET | Source: Teva Pharmaceutical Industries Ltd; Alvotech

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...
January 29, 2025 07:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023;AUSTEDO® - exceeding $1.6 billion in revenues, surpassing 2024 outlook;AJOVY® - global annual...
January 27, 2025 06:00 ET | Source: Teva Pharmaceutical Industries Ltd; Alvotech

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...
January 13, 2025 22:26 ET | Source: Teva Pharmaceutical Industries Ltd

Teva gibt Zusammenarbeit zur Vermarktung des Formycon Biosimilar-Kandidaten für Eylea® (Aflibercept) in großen Teilen Europas und in Israel bekannt

Klinge Biopharma GmbH (Klinge) besitzt die exklusiven weltweiten Vermarktungsrechte für FYB203, Formycons Biosimilar-Kandidat für Eylea®1Die Vereinbarung basiert auf der bewährten und erfolgreichen...
January 13, 2025 22:26 ET | Source: Teva Pharmaceutical Industries Ltd

Teva annonce un partenariat en vue de commercialiser le candidat biosimilaire de Formycon à Eylea® (aflibercept) dans la majeure partie de l’Europe et en Israël

Klinge Biopharma GmbH (Klinge) détient les droits exclusifs de la commercialisation mondiale de FYB203, le candidat biosimilaire de Formycon, à Eylea®1L’accord repose sur la collaboration éprouvée et...
January 13, 2025 01:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1Agreement builds on the proven and successful collaboration of...
January 10, 2025 08:30 ET | Source: Teva Pharmaceutical Industries Ltd; Samsung Bioepis Co., Ltd.

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in...
December 23, 2024 16:30 ET | Source: Teva Pharmaceutical Industries Ltd

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 43rd...
December 20, 2024 16:30 ET | Source: Teva Pharmaceutical Industries Ltd

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year...